Full-Time
Confirmed live in the last 24 hours
AI platform for cardiovascular disease diagnosis
$127k - $142kAnnually
Senior
New York, NY, USA
Some roles require you to be on-site in a location.
Cleerly Health focuses on improving the diagnosis and treatment of heart disease through its digital healthcare platform. The company utilizes artificial intelligence to analyze coronary computed tomography angiography (CCTA) imaging, which helps clinicians detect atherosclerosis, a condition characterized by plaque buildup in the arteries, at an earlier stage. Cleerly's platform converts complex imaging data into clear insights, allowing healthcare providers to create personalized treatment plans for their patients. This approach stands out from competitors by offering a more detailed evaluation of heart disease, including the ability to analyze and quantify different types of plaque, which aids in accurately assessing a patient's risk of heart attack. Cleerly's goal is to enhance patient outcomes and provide financial benefits to healthcare providers through its digital cardiovascular care management program.
Company Size
51-200
Company Stage
Series C
Total Funding
$406.4M
Headquarters
New York City, New York
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, and vision plans
Stock Options
401(k) matching program
Company wide holidays
Self-managed PTO
Denver-based Cleerly, known for using AI to evaluate coronary CT angiography (CCTA) images, has joined forces with San Francisco-based Bunkerhill Health, pioneers in AI-powered early detection software, to expand the reach of both companies' FDA-cleared solutions.
Cleerly's recent funding round was led by significant venture capital firms, including GGV Capital and RRE Ventures, among others, reflecting a growing investor interest in health tech solutions.
Cleerly, a cardiovascular imaging startup, has announced a significant $106 million Series C extension round led by Insight Partners, with participation from Battery Ventures.
Although heart disease is the leading cause of death in the United States, a significant portion of people who experience heart attacks are unaware that
Cleerly, a Denver-based cardiovascular imaging company, raised $106 million in funding. The round was led by Insight Partners and included Battery Ventures, along with existing investors. The funds will be used to scale commercial growth and clinical evidence generation. Cleerly, led by CEO James K. Min, MD, offers FDA-cleared AI-driven solutions for coronary artery disease phenotyping using advanced CT imaging.